EZALLOR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ezallor, and what generic alternatives are available?
Ezallor is a drug marketed by Sun Pharm and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in EZALLOR is rosuvastatin calcium. There are forty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the rosuvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ezallor
A generic version of EZALLOR was approved as rosuvastatin calcium by WATSON LABS INC on April 29th, 2016.
Summary for EZALLOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EZALLOR |
| DailyMed Link: | EZALLOR at DailyMed |
US Patents and Regulatory Information for EZALLOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | EZALLOR SPRINKLE | rosuvastatin calcium | CAPSULE;ORAL | 208647-001 | Dec 18, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | EZALLOR SPRINKLE | rosuvastatin calcium | CAPSULE;ORAL | 208647-004 | Dec 18, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | EZALLOR SPRINKLE | rosuvastatin calcium | CAPSULE;ORAL | 208647-002 | Dec 18, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | EZALLOR SPRINKLE | rosuvastatin calcium | CAPSULE;ORAL | 208647-003 | Dec 18, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
